摘要
目的:观察重组人尿激酶原(rhPro-UK)经导管溶栓(CDT)治疗急性髂股深静脉血栓(DVT)的临床疗效和不良反应。方法:回顾性分析2016年10月-2018年12月行CDT治疗的66例急性髂股DVT患者临床资料,其中33例采用rh Pro-UK行CDT治疗(观察组),33例采用尿激酶(UK)行CDT治疗(对照组)。比较两组患者的相关临床指标。结果:两组患者一般临床特征差异无统计学意义(均P>0.05)。观察组血栓溶解率(≥50%)明显高于对照组(81.8%vs. 60.6%,χ2=4.889,P<0.05),但在出院时两组的治疗有效率无统计学差异(81.8%vs.75.7%,χ~2=4.889,P>0.05)。两组患者均无明显出血、过敏等并发症。结论:rhPro-UK和UK都是治疗急性髂股DVT安全有效的溶栓药物,rhPro-UK在血栓溶解率方面明显优于UK,但其远期疗效需进一步评估。
Objective: To observe the clinical efficacy and adverse reactions of recombinant human prourokinase(rh Pro-UK) for catheter-directed thrombolysis(CDT) in treatment of acute iliofemoral deep venous thrombosis(DVT).Methods: The clinical data of 66 patients with acute iliofemoral DVT undergoing CDT therapy from October 2016 to December 2018 were retrospectively analyzed. Of the patients, 33 cases underwent CDT with rh Pro-UK(observation group), and the other 33 cases underwent CDT with urokinase(UK)(control group). The relevant clinical variables between the two groups of patients were compared. Results: There was no significant difference in general clinical features between the two groups of patients(all P>0.05) The thrombolytic rate(≥50%) in observation group was significantly higher than that in control group(81.8% vs. 60.6%, χ~2=4.889, P<0.05), but no significant difference was noted in treatment effective rate between the two groups at hospital discharge(81.8% vs. 75.7%, χ~2=4.889, P>0.05). No severe complications such as evident bleeding and anaphylactic reactions occurred in either group. Conclusion: Both rh Pro-UK and UK are safe thrombolytic agents for acute iliofemoral DVT. The thrombolytic rate of rh Pro-UK is superior to that of UK, but the long-term efficacy still needs to be further assessed.
作者
孙万里
温世奇
陈泉
史浩
龙洋
SUN Wanli;WEN Shiqi;CHEN Quan;SHI Hao;LONG Wng(Department of Vascular Surgery,Gansu Provincial Hospital,Lanzhou 730000,China)
出处
《中国普通外科杂志》
CAS
CSCD
北大核心
2019年第12期1507-1512,共6页
China Journal of General Surgery
基金
甘肃省人民医院院内科研基金资助项目（18GSSY4-11）
关键词
静脉血栓形成
髂静脉
股静脉
机械溶栓
纤维蛋白溶解药
Venous Thrombosis
Iliac Vein
Femoral Vein
Mechanical Thrombolysis
Fibrinolytic Agents
作者简介
第一作者:孙万里,甘肃省人民医院主治医师,主要从事血管外科方面的研究;第一作者:温世奇;通信作者:温世奇,Email:5zexue@163.com。
